Biointaxis

Biointaxis is an academic Biotech spin-off established in 2018 from the Health Sciences Research Institute Germans Trias i Pujol (IGTP) affiliated to the Universitat Autònoma de Barcelona (UAB), highly ranked University in Spain, located in Badalona, Barcelona, whose main activity is to dedicate scientific and technical research leading to the discovery, development, and commercialization of therapeutic products, treatments, and new genomic technologies for neurological diseases. Biointaxis’ Scientists are currently developing an advanced gene therapy treatment for Friedreich´s ataxia, a rare inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults. Biointaxis’ BTX-101 product has demonstrated in preclinical studies in small and large animals outstanding biodistribution, safety and efficacy profiles.